Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Health Education for Resistant Hyperprolactinemia
NCT04262024Phase 1Completed
- Sponsor
- Woman's Health University Hospital
- Start
- Feb 2020
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by Woman's Health University Hospital. Primary endpoint: Achievement of normoprolactinemia at 1 month. Started Feb 2020; status: completed.
Beyond the preview
Go deeper on NCT04262024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262024.